Early Phase Clinical Trial Units (EPCTU)
This Award Notice from the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a contract to PHARM-OLAM, LLC on January 14, 2021 to implement Early Phase Clinical Trial Units (EPCTU) to conduct Phase 0 to Phase II clinical trials and proof-of-concept studies domestically and internationally for new or tested investigational products such as small molecules, monoclonal antibodies, vaccines and other immunomodulatory products against infectious diseases, with Phase III studies conducted occasionally. The total value of the contract awarded to PHARM-OLAM, LLC is $346,610,277.00 to be paid over the period of performance.
75N93022D00015 Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases
2/15/22, 10:24 AM Early Phase Clinical Trial Units (EPCTU)
This Award Notice from the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a contract to DynPort Vaccine Company LLC on January 14, 2022 for $346,610,277 to implement multiple indefinite delivery/indefinite quantity contracts for Early Phase Clinical Trial Units. The contracts will support Phase 0 to Phase II clinical trials, including proof-of-concept studies in healthy and diseased human populations domestically and internationally, aided by bioanalysis when necessary, with a minimum value of $10,000 per award under the total estimated value of $346,610,277.
75N93022D00016 Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases
2/15/22, 10:34 AM Early Phase Clinical Trial Units (EPCTU)
The Award Notice from the National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a contract to PPD Development, L.P. to conduct Phase 0 through Phase II clinical trials, including proof-of-concept studies, domestically and internationally, to evaluate investigational products such as small molecules, monoclonal antibodies, vaccines, and other immunomodulatory products against infectious diseases. The contract has a value of $346,610,277, awarded on January 14, 2022 to fulfill the requirements of Request for Proposal RFP-NIAID-NIH-AI-75N93020R00023 which sought proposals for Early Phase Clinical Trial Units with a minimum value of $10,000 and maximum value of $346,610,277.
75N93022D00017 Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases
2/15/22, 10:42 AM Early Phase Clinical Trial Units (EPCTU)
This pre-solicitation notice seeks multiple Indefinite Delivery/Indefinite Quantity contracts to support Phase 0 through Phase II clinical trials of investigational products against infectious diseases through the National Institute of Allergy and Infectious Diseases. Contractors will collaborate with monitoring and data management partners to conduct domestic and international trials efficiently under a January 2022 anticipated award date and seven-year ordering period. Eligible offerors may submit proposals via the NIH electronic submission system for consideration to support the full range of early phase clinical trial activities, including administrative support, Phase 0 healthy volunteer studies, Phase I healthy volunteer studies, Phase I special population studies, and Phase II or III patient studies.
There is no set-aside designation. The main NAICS codes are 541715 and 541712, with PSC codes R425 and R499. No potential incumbents or current contractors are named. The pre-solicitation notice does not provide possible award values or budget ranges. Contractors will support Phase 0 through Phase III clinical trials of investigational infectious disease products over a seven-year ordering period beginning in January 2022.
RFP-NIAID-NIH-AI-75N93020R00023 Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases
11/19/20, 8:52 AM Early Phase Clinical Trial Units (EPCTU)
The National Institute of Allergy and Infectious Diseases awarded a contract to ICON Government and Public Health Solutions, Inc. to conduct Phase 0 through Phase II clinical trials domestically and internationally for small molecules, monoclonal antibodies, vaccines, and other immunomodulatory products against infectious diseases. The total value of the multiple award indefinite delivery contracts was estimated between $10,000 and $346,610,277. ICON Government and Public Health Solutions, Inc. was awarded $346,610,277 on January 14, 2022 to provide Early Phase Clinical Trial Units services.
75N93022D00018 Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases
2/15/22, 10:53 AM